This is an information message
We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.
CEBU CITY, Philippines — Local health officials here will be looking into reports of hoarding and price manipulation of medicines used to treat COVID-19. The Department of Health in Central Visayas (DOH-7) is set to meet with…
CEBU CITY, Philippines — The Cebu City Emergency Operations Center (EOC) is urging the Department of Trade and Industries (DTI) and the Department of Health (DOH) to control the prices of essential medicines being used for COVID-19…
CEBU CITY, Philippines – The Capitol has provided additional medicines and equipment to aid hospitals in the province as the surge of COVID-19 cases continues. Data from the Provincial Health Office showed that the four provincial and…
Paris, France—The anti-viral drug remdesivir should not be used to treat Covid-19 patients no matter how severe their illness as it has “no important effect” on survival chances, the World Health Organization said Friday, November 20, 2020.…
MANILA, Philippines — The antiviral drug remdesivir which is being eyed as a treatment for the coronavirus disease 2019 (COVID-19) has so far shown “positive effects” on some patients taking it. However, such findings are not…
NEW DELHI — India’s ability to deliver cost-effective and quality generic drugs, such as those that helped millions living with HIV, earned it the reputation of being the “pharmacy of the world”. This attribute has come into…
TOKYO — Japan plans to authorize Thursday the antiviral drug remdesivir to treat coronavirus patients, the government said, with an eye to approving another medication Avigan this month. This would make Japan the second country to approve…
The U.S. government said it is working to make the antiviral medication remdesivir available to patients as quickly as possible. “What it has proven is that a drug can block this virus,” said Dr. Anthony Fauci, the…
This is an information message
We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.